The opioid antagonist naltrexone reduces the reinforcing effects of Δ9-tetrahydrocannabinol (THC) in squirrel monkeys

被引:83
作者
Justinova, Z
Tanda, G
Munzar, P
Goldberg, SR
机构
[1] NIDA, US Dep HHS,NIH, Intramural Res Program, Behav Neurosci Res Branch,Preclin Pharmacol Sect,, Baltimore, MD 21224 USA
[2] NIDA, US Dept HHS,NIH, Intramural Res Program, Medicat Discovery Res Branch,Psychobiol Sect, Baltimore, MD 21224 USA
[3] ALEXZA Mol Delivery Corp, Palo Alto, CA 94303 USA
基金
美国国家卫生研究院;
关键词
Delta(9)-tetrahydrocannabinol (THC); cocaine; naltrexone; drug self-administration; squirrel monkeys; marijuana;
D O I
10.1007/s00213-003-1693-6
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Rationale. Experimental evidence from animal studies suggests reciprocal functional interactions between endogenous brain cannabinoid and opioid systems. There is recent evidence for a role of the opioid system in the modulation of the reinforcing effects of synthetic cannabinoid CB1 receptor agonists in rodents. Since Delta(9)-tetrahydrocannabinol (THC), the natural psychoactive ingredient in marijuana, is actively and persistently self-administered by squirrel monkeys, this provides an opportunity to directly study involvement of opioid systems in the reinforcing effects of THC in non-human primates. Objectives. To study the effects of naltrexone, an opioid antagonist, on THC self-administration behavior in squirrel monkeys. Methods. Monkeys pressed a lever for intravenous injections of THC under a ten-response, fixed-ratio (FR) schedule with a 60-s time-out after each injection. Effects of pre-session treatment with naltrexone (0.03-0.3 mg/kg intramuscularly, 15 min before session) for 5 consecutive days on self-administration of different doses of THC (2-8 mug/kg per injection) were studied. Results. Self-administration responding for THC was significantly reduced by pretreatment with 0.1 mg/kg naltrexone for five consecutive daily sessions. Naltrexone pretreatment had no significant effect on cocaine self-administration responding under identical conditions. Conclusions. Self-administration behavior under a fixed-ratio schedule of intravenous THC injection was markedly reduced by daily pre-session treatment with naltrexone, but remained above saline self-administration levels. These findings demonstrate for the first time the modulation of the reinforcing effects of THC by an opioid antagonist in a non-human primate model of marijuana abuse.
引用
收藏
页码:186 / 194
页数:9
相关论文
共 53 条
[1]   NALOXONE ATTENUATION OF THE EFFECT OF COCAINE ON REWARDING BRAIN-STIMULATION [J].
BAIN, GT ;
KORNETSKY, C .
LIFE SCIENCES, 1987, 40 (11) :1119-1125
[2]  
BEARDSLEY PM, 1986, J PHARMACOL EXP THER, V239, P311
[3]   Involvement of the opioid system in the anxiolytic-like effects induced by Δ9-tetrahydrocannabinol [J].
Berrendero, F ;
Maldonado, R .
PSYCHOPHARMACOLOGY, 2002, 163 (01) :111-117
[4]   COMPARISON OF SOME PHARMACOLOGICAL ACTIONS OF MORPHINE AND DELTA-9-TETRAHYDROCANNABINOL IN MOUSE [J].
BLOOM, AS ;
DEWEY, WL .
PSYCHOPHARMACOLOGY, 1978, 57 (03) :243-248
[5]   Intracerebral self-administration of the cannabinoid receptor agonist CP 55,940 in the rat: interaction with the opioid system [J].
Braida, D ;
Pozzi, M ;
Parolaro, D ;
Sala, M .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 413 (2-3) :227-234
[6]   Conditioned place preference induced by the cannabinoid agonist CP 55,940: Interaction with the opioid system [J].
Braida, D ;
Pozzi, M ;
Cavallini, R ;
Sala, M .
NEUROSCIENCE, 2001, 104 (04) :923-926
[7]   DELTA-9-TETRAHYDROCANNABINOL PRODUCES NALOXONE-BLOCKABLE ENHANCEMENT OF PRESYNAPTIC BASAL DOPAMINE EFFLUX IN NUCLEUS-ACCUMBENS OF CONSCIOUS, FREELY-MOVING RATS AS MEASURED BY INTRACEREBRAL MICRODIALYSIS [J].
CHEN, JP ;
PAREDES, W ;
LI, J ;
SMITH, D ;
LOWINSON, J ;
GARDNER, EL .
PSYCHOPHARMACOLOGY, 1990, 102 (02) :156-162
[8]   Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats [J].
De Vries, TJ ;
Homberg, JR ;
Binnekade, R ;
Raaso, H ;
Schoffelmeer, ANM .
PSYCHOPHARMACOLOGY, 2003, 168 (1-2) :164-169
[9]  
DEWEY WL, 1986, PHARMACOL REV, V38, P151
[10]  
EMMERSON PJ, 1994, J PHARMACOL EXP THER, V271, P1630